September 5, 2017 07:37 AM EDT

Insmed shares soar as PhIII lung disease study proves positive, pointing to quick FDA pitch

Shares of Insmed $INSM rocketed up 133% in premarket trading on Tuesday after the biotech reported that its Phase III study had hit the …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In­smed shares soar as PhI­II lung dis­ease study proves pos­i­tive, point­ing to quick FDA pitch